QA
GALT icon

Quattro Advisors’s Galectin Therapeutics GALT Stock Holding History

Quattro Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-634
Closed -$2.64K – 240
2025
Q4 		$2.64K Buy
+634
New +$3.34K ﹤0.01% 367

Other funds holding GALT

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Quattro Advisors's GALT Position: Q1 2026 in Review

Quattro Advisors sold out of Galectin Therapeutics (GALT) in Q1 2026, closing a stake of 634 shares — an estimated $2.64K sold.

Quattro Advisors first reported a position in GALT in Q4 2025 and held it in 1 quarter. The position peaked at $2.64K in Q4 2025. 99 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

  • Quattro Advisors reported no remaining Galectin Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Quattro Advisors sold 634 Galectin Therapeutics shares in Q1 2026, an estimated $2.64K.
  • Quattro Advisors first reported a position in Galectin Therapeutics in Q4 2025 and held it in 1 quarter.
  • Quattro Advisors's Galectin Therapeutics position peaked at $2.64K in Q4 2025.
  • 99 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on Quattro Advisors's 13F filing for Q1 2026, filed 15 May 2026.